Randall Kemp
Family Medicine · Seminole, OKNPI 1326043803
Payments from drug & device makers
Across 297 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$796
- Lilly USA, LLC$467
- Novo Nordisk$266
- Amarin Pharma, Inc.$229
- Novartis$202
- plus $1K from 28 others
What the payments were for
- Speaking & faculty fees$200%
- Food & beverage$4,37199%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $1,175 |
| AstraZeneca | 54 | $796 |
| Lilly USA, LLC | 34 | $467 |
| Novo Nordisk | 16 | $266 |
| Amarin Pharma, Inc. | 15 | $229 |
| Novartis | 13 | $202 |
| Pfizer | 22 | $182 |
| Amgen | 11 | $169 |
| Sanofi-aventis U.S. LLC | 8 | $155 |
| Sunovion Pharmaceuticals Inc. | 7 | $110 |
| Mylan Specialty L.p. | 5 | $104 |
| GSK | 7 | $91 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Merck | 2 | $34 |
| Boehringer Ingelheim | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Aytu Biopharma, Inc. | 2 | $26 |
| Boston Scientific | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Radius Health, Inc. | 1 | $21 |
| Integra Lifesciences Corporation | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Biogen | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Bayer | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Abbott | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$4,421 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 720 | $219,827 |
| Invega SustennaPaliperidone Palmitate | 50 | $158,742 |
| TrulicityDulaglutide | 82 | $83,734 |
| NuedextaDextromethorphan Hbr/Quinidine | 98 | $73,332 |
| IngrezzaValbenazine Tosylate | 17 | $66,341 |
| FarxigaDapagliflozin Propanediol | 142 | $44,839 |
| JanuviaSitagliptin Phosphate | 157 | $44,403 |
| OzempicSemaglutide | 40 | $39,870 |
| MyrbetriqMirabegron | 132 | $31,212 |
| Potassium Chloride | 737 | $26,684 |
| VraylarCariprazine Hcl | 38 | $26,596 |
| JardianceEmpagliflozin | 84 | $26,593 |
| Budesonide | 81 | $24,849 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 76 | $24,118 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 37 | $23,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $182 | $219,827720 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $17 | $182,022128 claims |
| Lilly USA, LLCTrulicity | $467 | $83,73482 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $27 | $73,33298 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $33 | $59,378194 claims |
| AbbVieVraylar, Linzess | $1,175 | $47,56789 claims |
| AstraZenecaFarxiga | $796 | $44,839142 claims |
| MerckJanuvia | $34 | $44,403157 claims |
| Novo NordiskOzempic | $266 | $39,87040 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $31,212132 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $91 | $20,82640 claims |
| NovartisEntresto | $202 | $13,38050 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Seminole
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.